{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:10:23Z","timestamp":1787022623115,"version":"build-2736575974"},"reference-count":48,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2023-0014_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The peritoneal regression grading score (PRGS) is a four-tied pathologic score measuring tumor regression in biopsies from patients with peritoneal metastasis (PM) receiving chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2023-0014_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective analysis of a prospective registry (NCT03210298) analyses 97 patients with isolated PM under palliative chemotherapy. We examined the predictive value of the initial PRGS for overall survival (OS) and the prognostic value of PRGS in repeated peritoneal biopsies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2023-0014_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 36 (37.1\u202f%) patients with an initial mean PRGS\u22642 had a longer median OS (12.1\u00a0months, CI 95\u202f% 7.8\u201316.4) vs. 8.0\u00a0months (CI 95\u202f% 5.1\u201310.8\u00a0months) in 61 (62.9\u202f%) patients with PRGS\u22653 (p=0.02) After stratification, the initial PRGS was an independent predictor of OS (Cox-regression, p&lt;0.05). Out of 62 patients receiving\u2265two chemotherapy cycles, 42 (67.7\u202f%) had a histological response (defined as a lower or stable mean PRGS in successive therapy cycles), and 20 (32.3\u202f%) progressed (defined as an increasing mean PRGS). PRGS response was associated with a longer median OS (14.6\u00a0months, CI 5\u201395\u202f% 6.0\u201323.2) vs. 6.9 (CI 5\u201395\u202f% 0.0\u201315.9) months. PRGS response was prognostic in the univariate analysis (p=0.017). Thus, PRGS had both a predictive and prognostic significance in patients with isolated PM receiving palliative chemotherapy in this patient cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2023-0014_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first evidence for the independent predictive and prognostic significance of PRGS in PM. These encouraging results need validation in an adequately powered, prospective study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2023-0014","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:50:41Z","timestamp":1684432241000},"page":"55-63","source":"Crossref","is-referenced-by-count":18,"title":["Peritoneal regression grading score (PRGS): first evidence for independent predictive and prognostic significance"],"prefix":"10.1515","volume":"8","author":[{"given":"Janina","family":"Baake","sequence":"first","affiliation":[{"name":"National Center for Pleura and Peritoneum, Comprehensive Cancer Center South-Western Germany , T\u00fcbingen-Stuttgart , Germany"},{"name":"Department of General and Transplant Surgery , Eberhard-Karls-University T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgi","family":"Nadiradze","sequence":"additional","affiliation":[{"name":"National Center for Pleura and Peritoneum, Comprehensive Cancer Center South-Western Germany , T\u00fcbingen-Stuttgart , Germany"},{"name":"Department of General and Transplant Surgery , Eberhard-Karls-University T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Archid","sequence":"additional","affiliation":[{"name":"National Center for Pleura and Peritoneum, Comprehensive Cancer Center South-Western Germany , T\u00fcbingen-Stuttgart , Germany"},{"name":"Department of General and Transplant Surgery , Eberhard-Karls-University T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"K\u00f6nigsrainer","sequence":"additional","affiliation":[{"name":"National Center for Pleura and Peritoneum, Comprehensive Cancer Center South-Western Germany , T\u00fcbingen-Stuttgart , Germany"},{"name":"Department of General and Transplant Surgery , Eberhard-Karls-University T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"B\u00f6sm\u00fcller","sequence":"additional","affiliation":[{"name":"National Center for Pleura and Peritoneum, Comprehensive Cancer Center South-Western Germany , T\u00fcbingen-Stuttgart , Germany"},{"name":"Institute of Pathology, Eberhard-Karls-University T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Reymond","sequence":"additional","affiliation":[{"name":"National Center for Pleura and Peritoneum, Comprehensive Cancer Center South-Western Germany , T\u00fcbingen-Stuttgart , Germany"},{"name":"Department of General and Transplant Surgery , Eberhard-Karls-University T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Solass","sequence":"additional","affiliation":[{"name":"National Center for Pleura and Peritoneum, Comprehensive Cancer Center South-Western Germany , T\u00fcbingen-Stuttgart , Germany"},{"name":"Institute of Pathology, Eberhard-Karls-University T\u00fcbingen , T\u00fcbingen , Germany"},{"name":"Institute of Tissue Medicine and Pathology, University Bern , Bern , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"2023060816410821416_j_pp-2023-0014_ref_001","doi-asserted-by":"crossref","unstructured":"Schwartz, LH, Liti\u00e8re, S, de Vries, E, Ford, R, Gwyther, S, Mandrekar, S, et al.. RECIST 1.1-update and clarification: from the RECIST committee. Eur J\u00a0Cancer 2016;62:132\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081.","DOI":"10.1016\/j.ejca.2016.03.081"},{"key":"2023060816410821416_j_pp-2023-0014_ref_002","doi-asserted-by":"crossref","unstructured":"Solass, W, Struller, F, Horvath, P, K\u00f6nigsrainer, A, Sipos, B, Weinreich, FJ. Morphology of the peritoneal cavity and pathophysiological consequences. Pleura Peritoneum 2016;1:193\u2013201. https:\/\/doi.org\/10.1515\/pp-2016-0023.","DOI":"10.1515\/pp-2016-0023"},{"key":"2023060816410821416_j_pp-2023-0014_ref_003","doi-asserted-by":"crossref","unstructured":"Tozzi, R, Traill, Z, Campanile, RG, Kilic, Y, Baysal, A, Giannice, R, et al.. Diagnostic flow-chart to identify bowel involvement in patients with stage IIIC-IV ovarian cancer: can laparoscopy improve the accuracy of CT scan? Gynecol Oncol 2019;155:207\u201312. https:\/\/doi.org\/10.1016\/j.ygyno.2019.08.025.","DOI":"10.1016\/j.ygyno.2019.08.025"},{"key":"2023060816410821416_j_pp-2023-0014_ref_004","doi-asserted-by":"crossref","unstructured":"Melamed, A, Nitecki, R, Boruta, DM2nd, del Carmen, MG, Clark, RM, Growdon, WB, et al.. Laparoscopy compared with laparotomy for debulking ovarian cancer after neoadjuvant chemotherapy. Obstet Gynecol 2017;129:861\u20139. https:\/\/doi.org\/10.1097\/aog.0000000000001851.","DOI":"10.1097\/AOG.0000000000001851"},{"key":"2023060816410821416_j_pp-2023-0014_ref_005","doi-asserted-by":"crossref","unstructured":"Fukagawa, T. Role of staging laparoscopy for gastric cancer patients. Ann Gastroenterol Surg 2019;3:496\u2013505. https:\/\/doi.org\/10.1002\/ags3.12283.","DOI":"10.1002\/ags3.12283"},{"key":"2023060816410821416_j_pp-2023-0014_ref_006","doi-asserted-by":"crossref","unstructured":"Zorzato, PC, Zannoni, GF, Tudisco, R, Pasciuto, T, Di Giorgio, A, Franchi, M, et al.. External validation of a \u2019response score\u2019 after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response. Int J Gynecol Cancer 2020;30:67\u201373. https:\/\/doi.org\/10.1136\/ijgc-2019-000561.","DOI":"10.1136\/ijgc-2019-000561"},{"key":"2023060816410821416_j_pp-2023-0014_ref_007","doi-asserted-by":"crossref","unstructured":"Solass, W, Sempoux, C, Detlefsen, S, Carr, NJ, Bibeau, F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the peritoneal regression grading score (PRGS). Pleura Peritoneum 2016;1:99\u2013107. https:\/\/doi.org\/10.1515\/pp-2016-0011.","DOI":"10.1515\/pp-2016-0011"},{"key":"2023060816410821416_j_pp-2023-0014_ref_008","doi-asserted-by":"crossref","unstructured":"Taibi, A, Lo Dico, R, Kaci, R, Naneix, AL, Mathonnet, M, Pocard, M. Impact of preoperative chemotherapy on the histological response of patients with peritoneal metastases from colorectal cancer according to peritoneal regression grading score (PRGS) and TRG. Surg Oncol 2020;33:158\u201363. https:\/\/doi.org\/10.1016\/j.suronc.2020.02.014.","DOI":"10.1016\/j.suronc.2020.02.014"},{"key":"2023060816410821416_j_pp-2023-0014_ref_009","doi-asserted-by":"crossref","unstructured":"Benzerdjeb, N, Durieux, E, Tantot, J, Isaac, S, Fontaine, J, Harou, O, et al.. Prognostic impact of combined progression index based on peritoneal grading regression score and peritoneal cytology in peritoneal metastasis. Histopathology 2020;77:548\u201359. https:\/\/doi.org\/10.1111\/his.14092.","DOI":"10.1111\/his.14092"},{"key":"2023060816410821416_j_pp-2023-0014_ref_010","doi-asserted-by":"crossref","unstructured":"Tabchouri, N, Buggisch, J, Demtr\u00f6der, CR, Thiery, J, Rezniczek, G, Tempfer, CB, et al.. Pressurized intraperitoneal aerosol chemotherapy for colorectal peritoneal metastases. Ann Surg Oncol 2021;28:5275\u201386. https:\/\/doi.org\/10.1245\/s10434-020-09508-0.","DOI":"10.1245\/s10434-020-09508-0"},{"key":"2023060816410821416_j_pp-2023-0014_ref_011","doi-asserted-by":"crossref","unstructured":"Elleb\u00e6k, SB, Graversen, M, Detlefsen, S, Lundell, L, Fristrup, CW, Pfeiffer, P, et al.. Pressurized IntraPeritoneal aerosol chemotherapy (PIPAC)-directed treatment of peritoneal metastasis in end-stage colo-rectal cancer patients. Pleura Peritoneum 2020;5:20200109. https:\/\/doi.org\/10.1515\/pp-2020-0109.","DOI":"10.1515\/pp-2020-0109"},{"key":"2023060816410821416_j_pp-2023-0014_ref_012","doi-asserted-by":"crossref","unstructured":"Nielsen, M, Graversen, M, Elleb\u00e6k, SB, Kristensen, TK, Fristrup, C, Pfeiffer, P, et al.. Next-generation sequencing and histological response assessment in peritoneal metastasis from pancreatic cancer treated with PIPAC. J Clin Pathol 2021;74:19\u201324. https:\/\/doi.org\/10.1136\/jclinpath-2020-206607.","DOI":"10.1136\/jclinpath-2020-206607"},{"key":"2023060816410821416_j_pp-2023-0014_ref_013","doi-asserted-by":"crossref","unstructured":"Elleb\u00e6k, SB, Graversen, M, Detlefsen, S, Lundell, L, Fristrup, CW, Pfeiffer, P, et al.. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) of peritoneal metastasis from gastric cancer: a descriptive cohort study. Clin Exp Metastasis 2020;37:325\u201332. https:\/\/doi.org\/10.1007\/s10585-020-10023-5.","DOI":"10.1007\/s10585-020-10023-5"},{"key":"2023060816410821416_j_pp-2023-0014_ref_014","doi-asserted-by":"crossref","unstructured":"Di Giorgio, A, Schena, CA, El Halabieh, MA, Abatini, C, Vita, E, Strippoli, A, et al.. Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): a bidirectional approach for gastric cancer peritoneal metastasis. Surg Oncol 2020;34:270\u20135. https:\/\/doi.org\/10.1016\/j.suronc.2020.05.006.","DOI":"10.1016\/j.suronc.2020.05.006"},{"key":"2023060816410821416_j_pp-2023-0014_ref_015","doi-asserted-by":"crossref","unstructured":"Graversen, M, Detlefsen, S, Asmussen, J, Mahdi, B, Fristrup, C, Pfeiffer, P, et al.. Treatment of peritoneal carcinomatosis with pressurized IntraPeritoneal aerosol chemotherapy - PIPAC-OPC2. Pleura Peritoneum 2018;3:20180108. https:\/\/doi.org\/10.1515\/pp-2018-0108.","DOI":"10.1515\/pp-2018-0108"},{"key":"2023060816410821416_j_pp-2023-0014_ref_016","doi-asserted-by":"crossref","unstructured":"Horvath, P, Yurttas, C, Struller, F, B\u00f6sm\u00fcller, H, Lauer, UM, Nadalin, S, et al.. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases in solid organ graft recipients: first experience. Ann Transplant 2019;24:30\u20135. https:\/\/doi.org\/10.12659\/aot.911905.","DOI":"10.12659\/AOT.911905"},{"key":"2023060816410821416_j_pp-2023-0014_ref_017","doi-asserted-by":"crossref","unstructured":"Graversen, M, Detlefsen, S, Bjerregaard, JK, Fristrup, CW, Pfeiffer, P, Mortensen, MB. Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther Adv Med Oncol 2018;10:1758835918777036. https:\/\/doi.org\/10.1177\/1758835918777036.","DOI":"10.1177\/1758835918777036"},{"key":"2023060816410821416_j_pp-2023-0014_ref_018","doi-asserted-by":"crossref","unstructured":"Kurtz, F, Struller, F, Horvath, P, Solass, W, B\u00f6sm\u00fcller, H, K\u00f6nigsrainer, A, et al.. Feasibility, safety, and efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis: a registry study. Gastroenterol Res Pract 2018;2018:2743985. https:\/\/doi.org\/10.1155\/2018\/2743985.","DOI":"10.1155\/2018\/2743985"},{"key":"2023060816410821416_j_pp-2023-0014_ref_019","unstructured":"Merlin, JL. Bonds between circulating tumoral ADN (ctDNA) and the development of peritoneal carcinomatosis for patients under PIPAC (PIPADN). NCT04766502; 2022. www.clinicaltrials.gov [Accessed 30 Aug 2022]."},{"key":"2023060816410821416_j_pp-2023-0014_ref_020","unstructured":"Kim, G. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) and electrostatic PIPAC (ePIPAC) with paclitaxel in patients with peritoneal carcinomatosis. NCT05395910; 2022. www.clinicaltrials.gov [Accessed 30 Aug 2022]."},{"key":"2023060816410821416_j_pp-2023-0014_ref_021","unstructured":"Labidi-Galy, I. PIPAC with nab-paclitaxel and cisplatin in peritoneal carcinomatosis (Nab-PIPAC). NCT04000906; 2019. www.clinicaltrials.gov [Accessed 30 Aug 2022]."},{"key":"2023060816410821416_j_pp-2023-0014_ref_022","unstructured":"Di, Giorgio A. Combined nabpaclitaxel pressurized IntraPeritoneal aerosol chemotherapy with systemic nabpaclitaxel-gemcitabine chemotherapy for pancreatic cancer peritoneal metastases (Nab-PIPAC). NCT05371223; 2022. www.clinicaltrials.gov [Accessed 30 Aug 2022]."},{"key":"2023060816410821416_j_pp-2023-0014_ref_023","unstructured":"Ceelen, WP. Intraperitoneal aerosolized nanoliposomal irinotecan (Nal-IRI) peritoneal carcinomatosis from gastrointestinal cancer (PIPAC-NAL-IRI). NCT05277766; 2022. www.clinicaltrials.gov [Accessed 30 Aug 2022]."},{"key":"2023060816410821416_j_pp-2023-0014_ref_024","unstructured":"Kim, HH. Intraperitoneal paclitaxel plus systemic mFOLFOX6 (IPLUS). NCT03618758; 2018. www.clinicaltrials.gov [Accessed 30 Aug 2022]."},{"key":"2023060816410821416_j_pp-2023-0014_ref_025","unstructured":"So, J. Pressurized intraperitoneal Aerosol chemotherapy (PIPAC) with oxaliplatin in patients with peritoneal carcinomatosis (PIPAC). NCT03172416; 2017. www.clinicaltrials.gov [Accessed 30 Aug 2022]."},{"key":"2023060816410821416_j_pp-2023-0014_ref_026","unstructured":"Casella, F. PIPAC in multimodal therapy for patients with oligometastatic peritoneal gastric cancer (PIPAC_VEROne). NCT05303714; 2022. www.clinicaltrials.gov [Accessed 30 Aug 2022]."},{"key":"2023060816410821416_j_pp-2023-0014_ref_027","unstructured":"Chia, C. PIPAC for peritoneal metastases. NCT04956068; 2021. www.clinicaltrials.gov [Accessed 30 Aug 2022]."},{"key":"2023060816410821416_j_pp-2023-0014_ref_028","unstructured":"de Hingh, I. PIPAC for peritoneal metastases of colorectal cancer (CRC-PIPAC). NCT03246321; 2017. www.clinicaltrials.gov [Accessed 30 Aug 2022]."},{"key":"2023060816410821416_j_pp-2023-0014_ref_029","doi-asserted-by":"crossref","unstructured":"Solass, W, Sempoux, C, Carr, NJ, Bibeau, F, Neureiter, D, J\u00e4ger, T, et al.. Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis. Histopathology 2019;74:1014\u201324. https:\/\/doi.org\/10.1111\/his.13829.","DOI":"10.1111\/his.13829"},{"key":"2023060816410821416_j_pp-2023-0014_ref_030","doi-asserted-by":"crossref","unstructured":"Solass, W, Meisner, C, Kurtz, F, Nadiradze, G, Reymond, MA, B\u00f6sm\u00fcller, H. Peritoneal regression grading score (PRGS) in peritoneal metastasis: how many biopsies should be examined? Pleura Peritoneum 2022;7:179\u201385. https:\/\/doi.org\/10.1515\/pp-2022-0118.","DOI":"10.1515\/pp-2022-0118"},{"key":"2023060816410821416_j_pp-2023-0014_ref_031","unstructured":"Solass, W, Nadiradze, G, Reymond, MA, B\u00f6sm\u00fcller, H. The role of additional staining in the assessment of the Peritoneal Regression Grading Score (PRGS) in peritoneal metastasis of gastric origin. Appl Immunohistochem Mol Morphol, (in press)."},{"key":"2023060816410821416_j_pp-2023-0014_ref_032","doi-asserted-by":"crossref","unstructured":"Cady, B. Basic principles in surgical oncology. Arch Surg 1997;132:338\u201346. https:\/\/doi.org\/10.1001\/archsurg.1997.01430280012001.","DOI":"10.1001\/archsurg.1997.01430280012001"},{"key":"2023060816410821416_j_pp-2023-0014_ref_033","doi-asserted-by":"crossref","unstructured":"Chang, HH, Leeper, WR, Chan, G, Quan, D, Driman, DK. Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. Am J Surg Pathol 2012;36:570\u20136. https:\/\/doi.org\/10.1097\/pas.0b013e31824057e7.","DOI":"10.1097\/PAS.0b013e31824057e7"},{"key":"2023060816410821416_j_pp-2023-0014_ref_034","doi-asserted-by":"crossref","unstructured":"Fabris, L, Perugorria, MJ, Mertens, J, Bj\u00f6rkstr\u00f6m, NK, Cramer, T, Lleo, A, et al.. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int 2019;39(1 Suppl):63\u201378. https:\/\/doi.org\/10.1111\/liv.14098.","DOI":"10.1111\/liv.14098"},{"key":"2023060816410821416_j_pp-2023-0014_ref_035","doi-asserted-by":"crossref","unstructured":"Nizri, E, Bar-David, S, Aizic, A, Sternbach, N, Lahat, G, Wolf, I, et al.. Desmoplasia in lymph node metastasis of pancreatic adenocarcinoma reveals activation of cancer-associated fibroblasts pattern and T-helper 2 immune cell infiltration. Pancreas 2019;48:367\u201373. https:\/\/doi.org\/10.1097\/mpa.0000000000001261.","DOI":"10.1097\/MPA.0000000000001261"},{"key":"2023060816410821416_j_pp-2023-0014_ref_036","doi-asserted-by":"crossref","unstructured":"Lee, D, Ham, IH, Son, SY, Han, SU, Kim, YB, Hur, H. Intratumor stromal proportion predicts aggressive phenotype of gastric signet ring cell carcinomas. Gastric Cancer 2017;20:591\u2013601. https:\/\/doi.org\/10.1007\/s10120-016-0669-2.","DOI":"10.1007\/s10120-016-0669-2"},{"key":"2023060816410821416_j_pp-2023-0014_ref_037","doi-asserted-by":"crossref","unstructured":"Chetty, R, Gill, P, Govender, D, Bateman, A, Chang, HJ, Deshpande, V, et al.. International study group on rectal cancer regression grading: interobserver variability with commonly used regression grading systems. Hum Pathol 2012;43:1917\u201323. https:\/\/doi.org\/10.1016\/j.humpath.2012.01.020.","DOI":"10.1016\/j.humpath.2012.01.020"},{"key":"2023060816410821416_j_pp-2023-0014_ref_038","doi-asserted-by":"crossref","unstructured":"Karamitopoulou, E, Thies, S, Zlobec, I, Ott, K, Feith, M, Slotta-Huspenina, J, et al.. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches. Am J Surg Pathol 2014;38:1551\u20136. https:\/\/doi.org\/10.1097\/pas.0000000000000255.","DOI":"10.1097\/PAS.0000000000000255"},{"key":"2023060816410821416_j_pp-2023-0014_ref_039","doi-asserted-by":"crossref","unstructured":"Toussaint, L, Teixeira Farinha, H, Barras, JL, Demartines, N, Sempoux, C, H\u00fcbner, M. Histological regression of gastrointestinal peritoneal metastases after systemic chemotherapy. Pleura Peritoneum 2021;6:113\u20139. https:\/\/doi.org\/10.1515\/pp-2021-0118.","DOI":"10.1515\/pp-2021-0118"},{"key":"2023060816410821416_j_pp-2023-0014_ref_040","doi-asserted-by":"crossref","unstructured":"Sindayigaya, R, Dogan, C, Demtr\u00f6der, CR, Fischer, B, Karam, E, Buggisch, JR, et al.. Clinical outcome for patients managed with low-dose cisplatin and doxorubicin delivered as pressurized intraperitoneal aerosol chemotherapy for unresectable peritoneal metastases of gastric cancer. Ann Surg Oncol 2022;29:112\u20133. https:\/\/doi.org\/10.1245\/s10434-021-10860-y.","DOI":"10.1245\/s10434-021-10860-y"},{"key":"2023060816410821416_j_pp-2023-0014_ref_041","doi-asserted-by":"crossref","unstructured":"Graversen, M, Detlefsen, S, Ellebaek, SB, Fristrup, C, Pfeiffer, P, Mortensen, MB. Pressurized IntraPeritoneal Aerosol Chemotherapy with one minute of electrostatic precipitation (ePIPAC) is feasible, but the histological tumor response in peritoneal metastasis is insufficient. Eur J Surg Oncol 2020;46:155\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2019.08.024.","DOI":"10.1016\/j.ejso.2019.08.024"},{"key":"2023060816410821416_j_pp-2023-0014_ref_042","doi-asserted-by":"crossref","unstructured":"Ceribelli, C, Debs, T, Chevallier, A, Piche, MA, Bereder, JM. Initial experience of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a French hyperthermic intraperitoneal chemotherapy (HIPEC) expert center. Surg Endosc 2020;34:2803\u20136. https:\/\/doi.org\/10.1007\/s00464-020-07488-6.","DOI":"10.1007\/s00464-020-07488-6"},{"key":"2023060816410821416_j_pp-2023-0014_ref_043","doi-asserted-by":"crossref","unstructured":"Alyami, M, H\u00fcbner, M, Grass, F, Bakrin, N, Villeneuve, L, Laplace, N, et al..\u00a0Pressurised intraperitoneal aerosol chemotherapy: rationale,\u00a0evidence, and potential indications. Lancet Oncol 2019;20:e368\u201377. https:\/\/doi.org\/10.1016\/s1470-2045(19)30318-3.","DOI":"10.1016\/S1470-2045(19)30318-3"},{"key":"2023060816410821416_j_pp-2023-0014_ref_044","doi-asserted-by":"crossref","unstructured":"de Bree, E, Michelakis, D, Stamatiou, D, Romanos, J, Zoras, O. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum 2017;2:47\u201362. https:\/\/doi.org\/10.1515\/pp-2017-0010.","DOI":"10.1515\/pp-2017-0010"},{"key":"2023060816410821416_j_pp-2023-0014_ref_045","doi-asserted-by":"crossref","unstructured":"Mortensen, MB, Glehen, O, Horvath, P, H\u00fcbner, M, Hyung-Ho, K, K\u00f6nigsrainer, A, et al.. The ISSPP PIPAC database: design, process, access, and first interim analysis. Pleura Peritoneum 2021;6:91\u20137. https:\/\/doi.org\/10.1515\/pp-2021-0108.","DOI":"10.1515\/pp-2021-0108"},{"key":"2023060816410821416_j_pp-2023-0014_ref_046","doi-asserted-by":"crossref","unstructured":"Schneider, MA, Eden, J, Pache, B, Laminger, F, Lopez-Lopez, V, Steffen, T, et al.. Mutations of RAS\/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann Surg 2018;268:845\u201353. https:\/\/doi.org\/10.1097\/sla.0000000000002899.","DOI":"10.1097\/SLA.0000000000002899"},{"key":"2023060816410821416_j_pp-2023-0014_ref_047","doi-asserted-by":"crossref","unstructured":"Wang, R, Dang, M, Harada, K, Han, G, Wang, F, Pool Pizzi, M, et al.. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med 2021;27:141\u201351. https:\/\/doi.org\/10.1038\/s41591-020-1125-8.","DOI":"10.1038\/s41591-020-1125-8"},{"key":"2023060816410821416_j_pp-2023-0014_ref_048","doi-asserted-by":"crossref","unstructured":"Rezniczek, GA, J\u00fcngst, F, J\u00fctte, H, Tannapfel, A, Hilal, Z, Hefler, LA, et al.. Dynamic changes of tumor gene expression during repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with peritoneal cancer. BMC Cancer 2016;16:654. https:\/\/doi.org\/10.1186\/s12885-016-2668-4.","DOI":"10.1186\/s12885-016-2668-4"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/pp-2023-0014\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/pp-2023-0014\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T12:42:11Z","timestamp":1686228131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/pp-2023-0014\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,5,8]]},"published-print":{"date-parts":[[2023,6,8]]}},"alternative-id":["10.1515\/pp-2023-0014"],"URL":"https:\/\/doi.org\/10.1515\/pp-2023-0014","relation":{},"ISSN":["2364-768X"],"issn-type":[{"value":"2364-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]}}}